| Literature DB >> 20938119 |
Masaki Wato1, Tomoki Inaba, Hisashi Ishikawa, Shigenao Ishikawa, Nobuyuki Baba, Masatsugu Miyoshi, Tomonori Senoh, Takuya Nagano, Koichi Takaguchi, Seishiro Watanabe, Kozo Kawai.
Abstract
A 63-year-old man with Stage IVa pancreas tail cancer was admitted for a distal pancreatectomy and splenectomy; adjuvant chemotherapy with gemcitabine was also administered. The chemotherapy was terminated after 16 courses due to hemolytic anemia, thrombocytopenia and renal dysfunction. Plasma exchange was performed; however the patient's renal function was diminished, requiring chronic hemodialysis. Physicians should be cautious of hemolytic uremic syndrome as a possible adverse reaction to gemcitabine and be aware that tests are needed for its early detection.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20938119
Source DB: PubMed Journal: Nihon Shokakibyo Gakkai Zasshi ISSN： 0446-6586